BridgeBio Pharma (BBIO) is scheduled to announce Q3 earnings results on Wednesday, October 29th, after market close. The consensus EPS Estimate is -$0.78 (+9.3% ...
11h
BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on ...
Analysts estimate that BridgeBio Pharma will report an earnings per share (EPS) of $-0.82. The announcement from BridgeBio ...
Zacks Investment Research on MSN
BridgeBio Pharma (BBIO) Soars 17.1%: Is Further Upside Left in the Stock?
BridgeBio Pharma (BBIO) shares ended the last trading session 17.1% higher at $63.56. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.
BioMarin no longer expects to hit its $4 billion revenue target by 2027, citing various market factors such as impending ...
Bridgebio Pharma says it will seek U.S. approval of BBP-418 for LGMD2i after Phase 3 trial data showed a range of benefits ...
Fintel reports that on October 27, 2025, HC Wainwright & Co. maintained coverage of BridgeBio Pharma (NasdaqGS:BBIO) with a ...
The search for a treatment for limb-girdle muscular dystrophy was started by the family of former Bank of America Corp. CEO ...
We recently published 10 Big Names Crushing Wall Street. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the top-performing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback